clinoptilolite and Diarrhea

Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder with poor response to treatment. IBS with predominant diarrhea (IBS-D) is accompanied by abdominal pain as well as high stool frequency and urgency. Purified clinoptilolite-tuff (PCT), which is approved by the Food and Drug Administration for use as a dietary supplement with the brand name G-PUR. To assess whether symptoms of IBS-D can be ameliorated by oral treatment with PCT.. In this randomized, placebo-controlled, double-blind pilot study, 30 patients with IBS-D diagnosis based on Rome IV criteria were enrolled. Following a 4-wk run-in phase, 14 patients were randomized to receive a 12-wk treatment with G-PUR. The proportions of SGA of Relief responders after 12 wk were comparable in both groups, namely 21% in the G-PUR. In this randomized, double-blind, placebo-controlled study, the PCT product, G-PUR

Topics: Abdominal Pain; Diarrhea; Double-Blind Method; Humans; Irritable Bowel Syndrome; Pilot Projects; Treatment Outcome

Patients with neuroendocrine tumors (NETs) of the gastrointestinal tract suffer frequently from chronic diarrhea. A well characterized medical advice containing zeolite (Detoxsan. To overcome the therapy-refractory diarrhea of patients with NETs by the zeolite containing medical advice Detoxsan. A total of 20 patients (12 female and 8 male) suffering from diarrhea either by its frequency or from watery stool caused by NETs were included. In each patient, the diagnosis had been confirmed by histology and somatostatin receptors expression proven by positron emission tomography/computed tomography using Ga-68-labeled somatostatin analogs. All patients received standard-of-care pharmacotherapy and were additionally given Detoxsan. All patients enrolled in this pilot study did not only suffer from NETs, but also from comorbidities and treatment-resistant diarrhea. There was insufficient control of diarrhea, most probably due to the secretion of hormones like serotonin produced by the slowly growing and highly differentiated NETs. All patients only took Detoxsan. Detoxsan

Topics: Adsorption; Adult; Aged; Aged, 80 and over; Aluminum Silicates; Carcinoid Tumor; Comorbidity; Diarrhea; Female; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pilot Projects; Powders; Somatostatin; Treatment Outcome; Zeolites

The effects of feeding clinoptilolite on hematology, performance, and health of newborn Balouchi lambs were evaluated in this experiment. In a completely randomized design, 30 newborn lambs were allocated to three groups and fed by basal diet (C0; without clinoptilolite) and C1 and C2 (the basal diet plus 1.5% and 3% clinoptilolite, respectively, for 6 weeks (3 weeks before and 3 weeks after weaning)). Blood samples were taken from all lambs, at the time when the animals were allocated to the experimental diet and at the end of each week of experiment, and analyzed for hematology, plasma fibrinogen, and total protein. Performance and health of all lambs were measured. Fecal consistency score and diarrhea severity were evaluated. There was no difference between lambs in case of hematological parameters. Lambs fecal consistency score and severity of diarrhea were lowest (P < 0.05) for lambs on C1 and C2 and highest for lambs on C0. Dry matter intake and feed conservation ratio were similar between the groups of lambs fed by different diets, but daily gain of lambs differed significantly (P < 0.05) and was higher in C2. It was concluded that addition of 3% clinoptilolite to starter diet of newborn lamb can reduce incidence and severity of diarrhea, although its effect on hematology and performance was negligible.

Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Animals, Newborn; Diarrhea; Hematology; Humans; Random Allocation; Sheep, Domestic; Zeolites

This study was conducted to assess the effect of dietary use of a clinoptilolite-rich tuff (Cp) on health status and performance of weaned, growing and finishing pigs and its compatibility during simultaneous oral administration of antimicrobials (AM) such as enrofloxacin (E) or salinomycin (S). Weaners (720) were assigned in 2 experimental groups and 4 subgroups based on the inclusion or not of Cp and AM in their feed (subgroups: NC, ES, Cp, Cp+ES) in order to evaluate their health status, under PWDS prevailing herd conditions. A second part of the trial aimed to the evaluation of piglet performance under conditions with minimized PWDS herd risks. For this purpose, a second set of 264 weaners were assigned in 2 groups and 4 subgroups, in a respective manner. All piglets remained on-trial until slaughtering age; Cp was incorporated in their feed at a rate of 2% from the day of weaning until slaughtering. The health status evaluation consisted in monitoring piglets for adverse effects related to Cp consumption, average daily diarrhoea scoring during weaning and mortality rate calculations throughout. Performance evaluation included individual weighing at the end of weaning, growing and fattening periods and feed consumption assessments. Average daily gain (ADG), average daily feed intake (ADFI) and feed conversion ration (FCR) on a pen basis were further calculated. Cp ingestion was well tolerated by the piglets. Simultaneous administration of Cp and AM in feed, resulted in less severe forms of PWDS, which had a shorter clinical course (P<0.05). Mortality decreased (P<0.05) during the weaning period due to AM administration. Concerning mean pig body weight at the end of each production phase, both Cp and AM had favorable effects (P<0.05). ADG estimated for the whole observation period was improved (P<0.05) by Cp-use along with AM. FCR improvements (P<0.05) were noticed during the different stages of growth due to AM or Cp administration, while Cp/AM interaction was noticed only at weaning (P<0.05).

Topics: Animals; Anti-Infective Agents; Diarrhea; Diet; Energy Intake; Enrofloxacin; Fluoroquinolones; Pyrans; Quinolones; Swine; Swine Diseases; Weaning; Weight Gain; Zeolites